Fab2-5 in complex with the capsid of Adeno-associated virus type 9

Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohorts.

MASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWG
YFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEG
CLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQ
YLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGP
AMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGIL
PGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVE
IEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL

EVQLVESGGGLVKPGGSPRLSCAASGFNFGSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKHSLY
LQVNSLRAEDTAVYYCARDPTTYGYNSAWDKKGWYFDLWGRGTLLTVS

VLTQPPSVSAAPGQMVTISCSGSSSNIGNDYISWYQQLPGTAPKLLIYDNNERPSGIPDRFSGSKSGTSATLGITGVQTG
DEADYYCGTWDSSLSAWVFGEGTKLTVV

National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

REAL-SPACE (WEIGHTED MAP SUM AT ATOM CENTERS)
Adeno-associated virus, AAV, capsid, Fab-complex, antibody, NAb, VIRUS, VIRAL PROTEIN-IMMUNE SYSTEM complex